Perioperative Von Willebrand Factor Dynamics are Associated with Liver Regeneration and Predict Outcome after Liver Resection. by Starlinger, Patrick et al.
 Perioperative Von Willebrand Factor Dynamics are Associated with Liver Regeneration 
and Predict Outcome after Liver Resection 
Patrick Starlinger1†, David Pereyra1, Stefanie Haegele1, Paul Braeuer1, Lukas 
Oehlberger2, Florian Primavesi3, Andreas Kohler4, Florian Offensperger1, Thomas 
Reiberger5 , Arnulf Ferlitsch5, Barbara Messner6, Guido Beldi4 , Stefan Staettner3, 
Christine Brostjan1, Thomas Gruenberger2 
1 Department of Surgery, Medical University of Vienna, General Hospital, Vienna, Austria 
2 Department of Surgery I, Rudolfstiftung Hospital, Vienna, Austria 
3 Department of Visceral, Transplantation and Thoracic Surgery, Medical University Innsbruck, Austria 
4 Department of Visceral Surgery and Medicine, University Hospital Inselspital Bern, Bern, Switzerland 
5 Department of Gastroenterology and Hepatology, Medical University of Vienna, General Hospital, Vienna, 
Austria 
6 Department of Cardiac Surgery, Medical University of Vienna, General Hospital, Vienna, Austria 
 
Contact Information: 
Patrick Starlinger, MD, PhD  
Department of Surgery, Medical University of Vienna 
Waehringer Guertel 18-20, 1090 Vienna, Austria 
Tel: +43-1-40400-21650 
E-mail: patrick.starlinger@meduniwien.ac.at 
Keywords: von Willebrand Factor Antigen, Platelets, Liver Resection, Liver Dysfunction, Morbidity, 
Mortality 
Abbreviations: Liver resection (LR), Liver dysfunction (LD), Hepatic venous pressure gradient (HVPG), 
Hepatocellular carcinoma (HCC), Von Willebrand Factor (vWF), Von Willebrand Factor antigen (vWF-Ag), 
Cholangiocellular carcinoma (CCC), International Study Group of Liver Surgery (ISGLS), Preoperative 
(PRE OP), Postoperative day (POD), Metastatic colorectal carcinoma (mCRC), Chemotherapy (CTx), 
Alcalic phosphatase (ALP), hexamethyldisalazin (HMDS), Intensive care unit (ICU), Receiver operating 
characteristic (ROC), Area under the curve (AUC), Liver sinusoidal endothelial cell (LSEC). 
Category: Original Article 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as
doi: 10.1002/hep.29651
This article is protected by copyright. All rights reserved.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
10
90
45
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
 2
Presented as a poster at EASLs ILC 2017 in Amsterdam 
Conflict of Interest: 
The authors who have taken part in this study declare that they do not have anything to disclose regarding 
conflict of interest with respect to this manuscript. 
 
Financial Support: 
The Association of Research on the Biology of Liver Tumors, Vienna, Austria, supported this work. 
 
Authors contributions:  
 
All listed authors have: 
 
- made substantial contributions to conception and design, and/or acquisition of data, and/or analysis and 
interpretation of data 
 
- participated in drafting the article or revising it critically for important intellectual content 
 
- given final approval of the version to be published. 
 
Electronic word count: 5997 words; 6 figures, 2 tables, 5 supplemental figures. 
 
Clinical Trial Registration: ClinicalTrials.gov Identifier: exploration set: NCT01700231, validation set: 
NCT02118545. 
Page 2 of 44
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 3
Abstract: 
Von Willebrand Factor (vWF) was found to mediate platelet influx during the early 
phase of liver regeneration in mice. Further, increased vWF-antigen (vWF-Ag) levels 
were shown to be predictive for outcome of patients with chronic liver disease. 
Accordingly, we aimed to assess the relevance of perioperative vWF-Ag dynamics in 
terms of liver regeneration and clinical outcome in patients undergoing liver resection 
(LR). Accordingly, we observed that vWF-Ag and its activity – estimated via ristocetin 
cofactor measurement – increased immediately after induction of liver regeneration and 
was associated with platelet accumulation within the liver. However, a significant vWF-
Ag burst was only observed in patients with unaffected postoperative liver regeneration. 
E-selectin, as an established marker for endothelial cell activation, was found to 
correlate with vWF-Ag in the liver vein after induction of liver regeneration (P=0.022). 
Preoperative vWF-Ag levels significantly predicted postoperative liver dysfunction (LD) 
(N=95, AUC:0.725, P=0.009). Furthermore, a cut-off of vWF-Ag≥182% was defined to 
identify patients with a higher risk for postoperative LD or morbidity. This was 
confirmed within an independent mulitcenter validation cohort (N=133). Ultimately, 
multivariable analysis revealed that vWF-Ag was an independent predictor of 
postoperative LD and morbidity. 
Conclusion: Within this study we were able to provide evidence that an initial vWF burst 
is required to allow for adequate platelet accumulation and concomitant liver 
regeneration after LR and might be abolished as a consequence of intrahepatic 
endothelial cell dysfunction. We were further able to reveal and validate the potential of 
preoperative vWF-antigen levels to predict poor postoperative outcome in patients 
undergoing LR. Despite the pathophysiological relevance of our findings, vWF-Ag seems 
to be a valuable tool for preoperative risk assessment in patients undergoing LR. 
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Introduction 
The most significant factor determining outcome after liver damage or resection 
represents the ability of the remnant liver to regenerate(1, 2). Growing evidence suggests, 
that an impairment of hepatic regeneration after liver surgery might culminate in 
postoperative liver dysfunction (LD), which is associated with a markedly increased risk 
of postoperative morbidity and mortality(2-4). During initiation of liver regeneration, 
platelets and their specific activation seem to be of crucial relevance(5). In this context, 
von Willebrand Factor (vWF) has recently been demonstrated to be of central relevance 
during the early period of liver regeneration by mediating platelet adhesion within the 
liver after partial hepatecomy in mice(6). In particular, Kirschbaum et al. demonstrated 
that platelet influx after liver resection (LR) was virtually absent in the presence of a 
neutralizing antibody against vWF. Further, vWF deficient mice showed markedly 
reduced liver regeneration(6). However, clinical evidence for this association is still 
missing. 
VWF is a 2050 amino acids long glycoprotein that is mostly organized in multimers. 
Activated endothelial cells release vWF-Ag as a response to certain stimuli, including 
high shear stress and portal hypertension(7, 8) Its primary functions are stabilization of 
factor VIII and cross linkage of platelets with the subendothelial matrix. Thus, vWF-Ag is 
widely known as a key player in coagulation and primary hemostasis(9). However, vWF-
Ag also plays a role in platelet mediated liver regeneration. In context of the liver, vWF-
antigen (vWF-Ag) has further been implicated as a non-invasive marker for outcome of a 
variety of chronic liver disease(8). It has been shown, that increased circulating vWF-Ag 
levels are associated with increased mortality rates in patients with cirrhosis and in 
patients with liver damage due to hepatitis C infection(10, 11). Moreover, patients with 
acute on chronic liver failure were found to have elevated levels of vWF-Ag compared to 
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healthy controls but also compared to patients with cirrhosis, and vWF-Ag levels were a 
valid tool to predict in-hospital mortality in these patients(12). In addition, multiple 
studies have reported that reduced liver function and portal hypertension are associated 
with increased levels of circulating vWF-Ag, that might be released from activated 
endothelial cells as a response to increased shear stress(5, 8, 13). However, the clinical 
relevance of vWF-Ag to assess preoperative liver function and concomitantly predict 
postoperative clinical outcome after LR has not been evaluated so far. Hence, the aim of 
this study was 1) to explore the dynamics, functional capacity and the pathophysiologic 
relevance of vWF-Ag in the process of early human liver regeneration, 2) to investigate 
the role of vWF-Ag as a predictive marker in patients undergoing LR and 3) to validate 
our data in an international multicenter fashion to present a clinically applicable tool for 
prediction of postoperative outcome prior to liver surgery. 
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Material and Methods 
Study Population and Sampling Time Points 
Initially an exploration cohort was prospectively recruited and patients were followed 
for a postoperative period of 90 days at the Medical University of Vienna. Patients with 
hepatocellular carcinoma (HCC), cholangiocellular carcinoma (CCC) or colorectal cancer 
liver metastasis (mCRC), were considered eligible for inclusion. Subsequently, as we 
observed a significant predictive potential of vWF-Ag for postoperative LD and clinical 
outcome, we validated our explorative results in a prospective set of patients 
representing a clinical routine cohort. Importantly, patients undergoing LR at 4 different 
institutions (General Hospital of Vienna [Austria], Rudolfstiftung Hospital [Austria], 
Paracelsus Medical University [Austria], University Hospital Inselspital Bern 
[Switzerland]) were included within this validation cohort. A sample size calculation on 
the data gathered within the exploratory cohort was performed using an online sample 
size calculator (sample-size.net): Concerning an observed mean difference of 42.429% 
and a standard deviation of 71.253% vWF-Ag, and an approximate incidence of LD of 
20%, the calculation suggested a sample size of 138 patients for a sufficiently powered 
validation cohort. Specific characteristics of all patients were prospectively recorded 
(Table 1). Baseline characteristics and surgical procedure of patients and preoperative 
variables of liver function, routine laboratory parameters and baseline liver pathology 
were recorded. Of note, no patient received platelet transfusions or was treated with 
terlipressin or comparable vasopressin analogs. Intraoperative transfusion of 
erythrocytes and perioperative medication with anti-platelet drugs were documented. 
VWF-Ag was evaluated one day prior to as well as one (POD1) and five (POD5) days 
after surgery. The extent of resection was classified as minor or major resections 
(<3segments=minor, ≥3segments=major), according to the IHPBA-Brisbane-2000 
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nomenclature(14). Further, postoperative outcome was prospectively documented and 
classified in LD, postoperative morbidity and postoperative mortality as described 
previously(5). For more detail refer to the supplemental methods section. 
We further assessed perioperative vWF-Ag dynamics during “early liver regeneration” 
in a subset of 30 patients undergoing hemihepatectomy. During hemihepatectomy we 
routinely start with the preparation of the hepato-duodenal ligament and the 
transection of the respective branches of the portal vein. As ligation of the portal 
branches is believed to trigger regenerative processes in the contralateral lobe(15), we 
collected blood from the remaining liver vein – i.e. from the regenerating liver lobe - 
after parenchymal transection. Furthermore, liver tissue samples were retrieved at the 
beginning of surgery and after parenchymal transection for electron microscopy 
analysis (description in supplemental methods section) in three patients undergoing 
major hepatectomy. 
The Institutional Ethics Committee approved the study and all patients gave written 
informed consent. Furthermore, the trial was registered at a clinical trials registry 
(ClinicalTrials.gov-Identifier: exploration set: NCT01700231, validation-set: 
NCT02118545). 
 
Measurement of vWF-Ag, Ristocetin Cofactor, ADAMTS13-Activity and Routine 
Laboratory Parameters 
Perioperative blood-parameters of liver function were measured in serum samples via 
local routine laboratory. To assure clinical relevance, also vWF-Ag was analyzed using 
routine laboratory analysis of each respective institution. Further, within our 
intraoperative sub-group, we assessed ristocetin cofactor (vWF:RiCo), a measure for 
vWF-Ag activity, in the routine laboratory, whereas the activity of A disintegrin and 
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metalloprotease with thrombospondin type 1 motif member 13 (ADAMTS13), the main 
regulating protease of vWF-multimer length, was assessed using a commercially 
available ELISA (TECHNOZYM® ADAMTS-13 Activity ELISA, Technoclone, Vienna, 
Austria). 
 
Statistical Analyses 
Statistical analyses were performed using SPSS 23 software (SPSS, Inc., Chicago, IL, USA) 
and were based on non-parametric tests for either paired or independent samples 
(Mann-Whitney U test, Wilcoxon test, chi-squared test, Spearman-Rho correlation). 
Further, receiver operating characteristic (ROC)-analysis was applied to assess the 
discriminatory potential of vWF-Ag between patients with or without LD and 
multivariable analysis was used to investigate independency of predictive markers for 
postoperative LD and morbidity. 
For more detailed elaboration of statistical analysis refer to the supplemental material. 
Boxplot illustrations are given without outliers and extreme values to improve the 
resolution of interquartile ranges. P-values <0.05 were considered statistically 
significant. 
To validate the ability of preoperative vWF-Ag to detect poor postoperative outcome, a 
ROC-curve analysis was performed. In addition, this statistical approach was used to 
identify the optimal cut-off level with the greatest accuracy of distinguishing high and 
low risk groups. 
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Results 
Patient Demographics 
A total of 95 patients suffering from either mCRC, HCC or CCC who underwent LR 
between 1/2012 and 12/2013 were included in our prospective exploratory study 
cohort (in 30 patients detailed intraoperative blood sampling was applied). 
Subsequently, additional 133 consecutive patients from 4 different institutions (General 
Hospital of Vienna: N=35, Rudolfstiftung Hospital: N=38, Paracelsus Private Medical 
University of Salzburg: N=35, University Hospital Inselspital Bern: N=25) and 2 
countries (Austria and Switzerland) were enrolled between 2/2014 and 7/2015 and 
served as a validation cohort. Of note, this international multicenter approach allows 
validation with high clinical relevance, as it reflects clinical routine among different 
institutions. Patient characteristics, outcome and laboratory parameters of patients from 
both groups are listed in Table 1. 
 
VWF-Ag Levels Increase after Partial Hepatectomy 
We initially assessed the perioperative time course of vWF-Ag blood levels in patients 
undergoing LR as illustrated in Fig.1A. In the exploration cohort, perioperative vWF-Ag 
concentrations revealed a distinct and significant increase on POD1 (median PRE 
OP=160.0%, median POD1=276.9%, P=0.001) and vWF-Ag levels further increased 
until POD5 (median PRE OP=160%, median POD5=336.0%, P=0.001; median 
POD1=276.9%, median POD5=336.0%, P=0.007). 
To evaluate whether the extent of LR would affect postoperative vWF-levels, vWF-Ag 
was analyzed in patients undergoing minor or major resection (Fig.1B). While 
preoperative vWF-Ag concentrations were found to be comparable in patients 
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undergoing major or minor LR, we found significantly deteriorated postoperative 
(POD1) vWF-Ag levels, in patients after major LR (median minor=252.5%, median 
major=312.0%, P=0.001). VWF-Ag levels further increased until POD5 and the trend of 
elevated vWF-Ag levels in patients undergoing major resection compared to those with 
minor resections could also be observed at this later time point. However, this 
observation did not reach statistical significance (median minor=279.0%, median major 
resection=377.0%, P=0.075; Fig.1B). 
As both erythrocyte transfusion and anti-platelet drugs might interfere with our 
readout, we subsequently evaluated perioperative dynamics of vWF-Ag in patients that 
did or did not receive intraoperative blood transfusion (Supplemental Fig.1A) and 
patients that were perioperatively treated with anti-platelet drugs (Supplemental 
Fig.1B). Importantly, we found similar dynamics as for our exploration cohort and could 
not assess any differences between the cohorts. 
 
Liver Cirrhosis and Diminished Liver Function are Associated with higher Levels of vWF-
Ag prior to Surgery 
When looking at dynamics of vWF-Ag between the perioperative time points, similar 
patterns were found in patients with fibrosis or cirrhosis (Supplemental Fig.2A), 
sinusoidal obstruction syndrome (Supplemental Fig.2B), steatosis (Supplemental 
Fig.2C) and steatohepatitis (Supplemental Fig.2D). In line with the current literature, we 
observed higher levels of vWF-Ag at baseline in patients suffering from cirrhosis 
compared to non-fibrotic patients (median no fibrosis=146.0 %, median 
cirrhosis=183.0 %, P=0.036). Further, we observed significantly higher levels of vWF-
Ag in patients with cirrhosis compared to patients with fibrosis on POD5 (median 
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fibrosis=335.5 %, median cirrhosis=420.0 %, P=0.039). Yet, patients suffering from 
fibrosis, steatosis, sinusoidal obstruction syndrome or steatohepatitis, did not show 
significant deviations in terms of vWF-Ag prior to surgery. In addition, we evaluated the 
relation of preoperative vWF-Ag to markers of liver damage (aspartate-
aminotransferase, alanine-aminotransferase, albumin), liver function (bilirubin, INR, 
MELD score), cholestasis (gamma-glutamyl transferase, alcalic phosphatase), and to 
preoperative platelet counts. Indeed, we were able to document significant, yet weak 
correlations with most of the mentioned markers, as visualized in Supplemental Fig. 3. 
Of note, there was no association between levels of vWF-Ag and platelet count prior to 
surgery (R=-0.103, P=0.321). 
 
Perioperative vWF-Ag Levels are Associated with Poor Postoperative Outcome 
Further, we aimed to evaluate the association of perioperative vWF-Ag levels and 
postoperative clinical outcome after LR. Patients suffering from postoperative LD were 
found to have significantly higher preoperative vWF-Ag values than patients that were 
not affected by postoperative LD (vWF-Ag median: no LD=158.7%, LD=194.3%, 
P=0.009). This elevation in vWF-Ag levels could also be observed on POD1 (median no 
LD=268.0%, median LD=325.0%; P=0.035; Fig.1C) and on POD5 (median no 
LD=304.3%, median LD=420.0%; P=0.002; Fig.1C). 
As postoperative LD is the main determinant for postoperative morbidity, we further 
compared perioperative vWF-Ag dynamics in patients with and without postoperative 
morbidity. Similar to LD, vWF-Ag levels were significantly increased in patients suffering 
from postoperative morbidity (PRE OP: median no morbidity=146.0%, median 
morbidity=171.6%, P=0.002; POD1: median no morbidity=240.5%, median 
Page 11 of 44
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 12
morbidity=317.0%, P=0.001; POD5: median no morbidity=274.2%, median 
morbidity=395.0%, P=0.001; Fig.1D). 
 
VWF-Ag Increases Immediately after Induction of Liver Regeneration 
As vWF-Ag has been suggested to be involved in the process of liver regeneration and as 
we had observed a striking association with clinical outcome in our exploration cohort, 
we subsequently aimed to generate a more detailed picture of perioperative vWF-Ag 
dynamics and its correlation to platelets. Using scanning electron microscopy, we were 
able to document a striking accumulation of blood cells, predominantly platelets, 
immediately after induction of liver regeneration (representative example is given in 
Fig.2A). Furthermore, in our subset of 30 patients, vWF-Ag increased immediately after 
induction of liver regeneration (i.e. 2h after portal vein ligation) in the liver vein 
(median PRE OP=138.5%, median liver vein=155.0%; P=0.014, Fig.2B). This increase 
was accompanied by a significant decrease of circulating platelets in the liver vein 
(median PRE OP=256x103/µl, median liver vein=150x103/µl; P=0.001, Fig.2B). 
 
Immediate vWF-Ag Increase is Associated with Platelet Accumulation and Postoperative 
Liver Dysfunction 
Subsequently, we evaluated whether immediate perioperative vWF-Ag dynamics were 
associated with postoperative liver function recovery. As for the entire cohort, we 
observed a trend towards elevated preoperative vWF-Ag levels in patients suffering 
from postoperative LD (median no LD=112.0%, median LD=161.0%; P=0.051, Fig.2C). 
Intriguingly, this difference was vanished in the liver vein after induction of liver 
regeneration (median no LD=152.0%, median LD=160.0%; P=0.501, Fig.2C). Of note, 
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vWF-Ag levels increased significantly after induction of liver regeneration only in 
patients without postoperative LD (median PRE OP=112.0%, median liver 
vein=152.0%; P=0.005, Fig.2C). Indeed, when calculating the fold induction of vWF-Ag, 
the association of the vWF-Ag increase with postoperative liver function recovery was 
even more evident (median no LD=1.3, median LD=1.0; P=0.043, Fig.2D). Interestingly, 
the incidence of postoperative LD was significantly elevated in patients without 
substantial induction of vWF-Ag (cut-off at 1.09-fold acc. Youden index; 0 of 12 [0.0%] in 
no increase group vs. 8 of 13 [61.5%] in increase group; P=0.002, Fig.2E). 
In line with experimental reports suggesting vWF to be crucially involved in platelet 
accumulation after induction of liver regeneration, we observed that the absolute vWF-
Ag level in the liver vein after induction of liver regeneration correlated with the 
reduction of platelet counts caused by accumulation within the liver (R=-0.580; 
P=0.030). Furthermore, we observed that patients with an evident reduction of 
platelets in the liver vein as compared to systemic preoperative levels (cut-off at 80%) 
had a significant increase in vWF-Ag after induction of liver regeneration, while patients 
without mentionable platelet accumulation tended to decrease in their vWF-Ag levels 
(median decrease=1.2, median no decrease=0.9; P=0.042, Fig.2F). 
 
Levels of vWF-Ag are closely related to its functional capacity in the early phase of liver 
regeneration 
As the amount of vWF-Ag does not necessarily correlate with its function, we aimed to 
characterize the functional capacity of this protein during the early phase of liver 
regeneration within our intraoperative cohort. As for vWF-Ag, we observed a rapid 
increase in vWF:RiCo, as a parameter of vWF-Ag function two hours after induction of 
liver regeneration (median PRE OP=132.0%, median liver vein=164.5%, P<0.001; 
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Fig.3A), and an additional increase on POD1 (median liver vein=164.5%, median 
POD1=291.0%, P<0.001; Fig.3A). We did not observe any significant differences in 
vWF:RiCo between patients with and without LD prior to the surgery or in the liver vein. 
However, on POD1, patients that developed postoperative LD were found to have 
significantly elevated vWF:RiCo values (median no LD=241.0%, median LD=395.5%, 
P=0.001; Fig.3A). 
Within our intraoperative cohort we also observed a strong and highly significant 
correlation of levels of vWF-Ag and its function estimated by vWF:RiCo at each time 
point (PRE OP: R=0.823, P<0.001; LV: R=0.704, P<0.001; POD1: R=0.691, P=0.006; 
Fig.3B). We further calculated the ratio of vWF:RiCo to vWF-Ag (Fig.3C). Regarding the 
perioperative dynamic, we observed a rapid increase already during early liver 
regeneration in the liver vein (median PRE OP=0.87, median liver vein=1.01, P=0.004; 
Fig.3C), with a subsequent decrease on POD1 (median liver vein=1.01, median 
POD1=0.94, P=0.036; Fig.3C). Interestingly, patients with postoperative LD tended to 
have lower values prior to surgery (median no LD=1.02, median LD=0.77, P=0.072; 
Fig.3C) and during early liver regeneration in the liver vein (median no LD=1.06, 
median LD=0.96, P=0.086; Fig.3C). 
Ultimately, we assessed ADAMTS13-activity, in this sub-group of patients, and observed 
similar dynamics for patients with and without LD. Perioperative dynamics showed a 
significant decrease on POD1 only, with no apparent differences in patients with and 
without LD (no LD: POD1=62.19%, PRE OP=88.59%, P=0.001; liver vein=95.50%, 
P=0.001; LD: POD1=58.62%, PRE OP=65.43%, P=0.028; liver vein=79.00%, P=0.0028; 
Fig.3D). 
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VWFhigh Patients Suffer from an Increased Incidence of Postoperative LD and Poor Clinical 
Performance 
We further aimed to quantify the potential of pre- and postoperative vWF-Ag levels to 
predict postoperative clinical outcome. Therefore, a ROC curve analysis was performed, 
revealing a significant association of preoperative vWF-Ag levels and postoperative LD 
with an area under the curve (AUC) of 0.725 (P=0.009, Fig.4A). Subsequently, a cut-off 
level of vWF-Ag≥182% was chosen to precisely identify patients with postoperative LD 
with a specificity of 78% and a sensitivity of 69%. To evaluate whether elevated 
preoperative vWF-Ag values would further translate into poor clinical performance, the 
incidence of postoperative LD and morbidity was compared between the risk groups. 
Accordingly, patients exceeding our cut-off level of vWF-Ag≥182% were found to suffer 
more frequently from postoperative LD (vWF-Ag<182%=5.9%, vWF-
Ag≥182%=33.3%, P=0.001; Fig.4A) and morbidity (vWF-Ag<182%=44.1%, vWF-Ag 
≥182%=74.1%, P=0.008; Fig.4A). 
As patients undergoing major resection are at higher risk to develop postoperative LD, 
we further performed a subgroup analysis of these patients. Accordingly, we observed a 
comparable predictive potential with an AUC of 0.7 (P=0.018) and patients exceeding 
our cut-off were found to suffer from an increased incidence of postoperative LD and 
morbidity (LD: vWF-Ag<182%=8.8%, vWF-Ag≥182%=50.0%, P=0.002; morbidity: 
vWF-Ag<182%=58.8%, vWF-Ag≥182%=83.3%, P=0.067). 
Additionally, we assessed the predictive potential of postoperative vWF-Ag levels for 
clinical outcome. A ROC curve analysis, based on vWF-Ag levels measured on POD1, was 
performed revealing a significant association of postoperative vWF-Ag levels and 
postoperative LD with an AUC of 0.683 (P=0.035; Fig.4B). Again, the ROC analysis was 
used to define a suitable cut-off level, which could be identified at vWF-Ag≥315%. In 
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patients who exceeded the postoperative cut-off level, incidences of LD and morbidity 
were significantly increased (LD: vWF-Ag<315%=8.3%, vWF-Ag≥315%=25.0%, 
P=0.029; morbidity: vWF-Ag<315%=40.0%, vWF-Ag≥315%=81.3%, P=0.001), as 
illustrated in Fig.4B. 
 
Prospective Validation of Preoperative vWF-Ag Levels to Predict Poor Postoperative 
Performance 
Given the clinical relevance to determine patients’ risk for adverse postoperative events 
prior to surgery, we further focused on preoperative vWF-Ag levels to predict clinical 
outcome after LR. In particular, we aimed to validate our results in a prospective 
independent validation cohort, in a multicenter/multinational setting (for details of 
these 133 patients see Table 1). Importantly, we were able to verify, that patients 
exceeding the preoperative cut-off level of vWF-Ag≥182% suffered from a significantly 
increased incidence of postoperative LD (vWF-Ag<182%=5.2%, vWF-
Ag≥182%=19.6%, P=0.009) and morbidity (vWF-Ag<182%=35.1%, vWF-
Ag≥182%=55.4%, P=0.020) which is illustrated in Fig.4C. 
We also aimed to validate the results of our subgroup analysis of patients undergoing 
major LR. Accordingly, we observed an even better predictive potential with an AUC of 
0.8 (P=0.005) and patients exceeding our cut-off were found to suffer from an increased 
incidence of postoperative LD and morbidity (LD: vWF-Ag<182%=7.0%, vWF-
Ag≥182%=33.3%, P=0.005; morbidity: vWF-Ag<182%=46.5%, vWF-
Ag≥182%=70.0%, P=0.039). 
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Patients with Elevated Preoperative Levels of vWF-Ag Demonstrate an Increased 
Incidence of Poor Postoperative Performance, ICU-Stay and Hospitalization: Entire Cohort 
To further increase the power of the analysis, we combined the exploration and 
validation set for additional analyses (N=228, Table 1), demonstrating significantly 
higher incidences of postoperative LD and morbidity in patients with preoperatively 
elevated vWF-Ag levels (LD: vWF-Ag<182%=5.5%, vWF-Ag≥182%=24.1%, odds ratio 
(OR)=5.437, 95%-confidence interval (CI)=2.27-13.01, P=0.001, Fig.5A; morbidity: 
vWF-Ag<182%=39.3%, vWF-Ag≥182%=61.4%, OR=2.461, 95%-CI=1.42-4.28, 
P=0.001, Fig.5B). In addition, patients with elevated preoperative vWF-Ag levels were 
also found to suffer from a prolonged intensive-care-unit (ICU) and hospital stay 
(hospitalization>10 days: vWF-Ag<182%=31.3%, vWF-Ag≥182%=47.5%, OR=1.99, 
95%-CI=1.34-3.49, P=0.016, Fig.5C; ICU stay>2 days: vWF-Ag<182%=9.0%, vWF-
Ag≥182%=26.0%, OR=3.538; 95%-CI=1.62-7.73, P=0.001, Fig.5D). Importantly, 
applying our cut-off, we observed a significantly higher incidence of postoperative 
mortality in patients with high preoperative vWF-Ag (vWF-Ag<182%=2.1%, vWF-
Ag≥182%=7.5%, OR=3.838; 95%-CI=0.93-15.78, P=0.047, Fig.5E). 
 
vWF-Ag Remains an Independent Marker for Postoperative LD and Morbidity upon 
Multivariable Analysis 
As we had observed a significant association of postoperative LD and vWF-Ag prior to 
LR, we aimed to explore whether vWF-Ag could independently predict postoperative LD. 
Therefore, MVA was performed on the entire cohort of 228 patients (evaluation and 
validation cohort). After step-wise forward selection only vWF-Ag, perioperative CTx, 
extent of resection and INR remained significant. The results from the final model fit are 
shown in Table 2A. 
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Similarly, we performed MVA for predictors of postoperative morbidity. After step-wise 
forward selection vWF-Ag, suffering from CCC and extent of resection remained 
significant. The results from the final model fit are shown in Table 2B. 
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Discussion 
To date the process of liver regeneration remains poorly understood. Nevertheless, 
platelets could be shown to play a central role during liver regeneration, most likely via 
releasing their cargo to promote cell cycle progression and proliferation (16, 17). Recently, 
Kirschbaum et al. demonstrated that platelet accumulation within the liver to promote 
liver regeneration is specifically relevant in the very early phase of liver regeneration 
after partial hepatectomy in mice (6). Within this investigation, we report on the first in 
human data on vWF-dependent platelet accumulation during liver regeneration. 
Furthermore, we demonstrate that an adequate increase of vWF-Ag after LR seems to be 
required to allow for sufficient postoperative hepatic regeneration. Additionally, we 
demonstrate that preoperative vWF-Ag is a valuable predictor for postoperative 
outcome in patients undergoing LR and validate our results using an independent 
prospective cohort from 4 different institutions, documenting the reproducibility and 
clinical relevance of our findings. 
Kirschbaum et al. were able to provide solid evidence for a critical relevance of vWF for 
platelet adhesion within the regenerating liver(6). Indeed, both blocking vWF via an 
antibody and knock-out of vWF lead to reduced liver regeneration in affected mice. In 
line with these findings, we could now document a significant increase of vWF-Ag within 
the liver vein already two hours after induction of liver regeneration. Moreover, we 
were able to validate our previous reports on platelet accumulation during liver 
regeneration in humans using scanning electron microscopy. This association was 
further displayed by a significant decrease of platelets in blood taken from the liver vein, 
compared to preoperative systemic platelet levels. Indeed, the extent of platelet 
decrease could also be shown to be vWF-dependent. Only patients with a significant 
increase of vWF-Ag demonstrated a mentionable decrease in platelets after passing the 
Page 19 of 44
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 20
regenerating liver. Furthermore, we observed that this adequate increase of vWF-Ag 
after LR seemed to be required to allow for sufficient postoperative liver regeneration. 
In particular, patients that were not able to significantly increase vWF-Ag after ligation 
of the portal vein were shown to more likely suffer from postoperative LD. Of note, the 
regenerative vWF-Ag burst was specifically abolished in patients with preoperatively 
increased vWF-Ag levels, which possibly reflects a state of liver sinusoidal endothelial 
cell (LSEC) exhaustion. Indeed, the rapid increase of vWF-Ag levels likely reflects its 
release from a preformed storage pool. As activated LSECs are capable of releasing vWF-
Ag from their Weibel-Palade bodies, they might represent a likely source for the increase 
of circulating vWF-Ag levels after LR. Of note, both in blood samples collected prior to 
the operation and from the liver vein of the regenerating lobe, a significant correlation of 
vWF-Ag with E-selectin, a specific marker for endothelial cell activation, could be 
observed (Supplemental Fig.4). This suggests that the regenerative vWF-Ag burst might 
predominantly be a result of endothelial cell activation. Indeed, LR was shown to cause a 
series of pathophysiological changes in the liver sinusoids, including augmented blood 
flow, increase in portal venous pressure and subsequently LSEC perturbation(15). 
Interestingly, the release of vWF from endothelial cells was shown to be associated to 
augmented shear stress as induced by an increase of portal venous pressure(18). Further, 
vWF has been proposed as a marker for disease progression in chronic liver disease and 
to be elevated in patients suffering from portal hypertension(8, 13). On the other hand, 
chronic portal hypertension was shown to lead to endothelial cell dysfunction(19) and 
hypoactive state of LSECs(20). With respect to the current literature, this lead us to 
hypothesize that patients presenting with high preoperative levels of vWF-Ag might 
suffer from underlying liver disease and/or sub-clinical portal hypertension. This 
hypothesis is further supported by a highly significant correlation between circulating 
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levels of vWF-Ag and soluble CD163, another non-invasive marker for portal 
hypertension, both prior to the operation (Supplemental Fig.6A) and intraoperatively 
(Supplemental Fig.5B). Importantly, soluble CD163 has been proposed as a marker of 
Kupffer cell activation, which is known to additionally contribute to portal 
hypertension(21), and can thus be considered pathomechanistically independent of 
elevated vWF-Ag levels. Interestingly, we found no significant association between levels 
of soluble CD163 and development of postoperative LD (Supplemental Fig.5C), which 
might indicate that the predictive potential of vWF-Ag for postoperative LD and 
complications is not exclusively due to its association to portal hypertension, but more 
likely related to the effects of vWF-dynamics on platelet accumulation during the early 
phase of liver regeneration. While sub-clinical portal hypertension might lead to 
perpetual activation of LSECs and concomitantly to a continuous release of vWF-Ag 
culminating in significantly elevated levels of vWF-Ag prior to the operation, these 
patients seem to be unable to respond with an adequate vWF-Ag burst after LR, leading 
to diminished platelet accumulation and subsequently to reduced delivery of platelet 
granule stored molecules required for an adequate induction of liver regeneration (for 
summary see Fig.6). Indeed, this is also nicely illustrated by our observation that 
circulating vWF-Ag levels were less predictive for postoperative outcome on POD1 when 
compared to preoperative values. As patients with normal basal vWF-Ag levels seem to 
be capable to respond to a certain stressor (such as liver resection) with an adequate 
vWF-Ag release, they align with levels of patients that display elevated basal vWF-Ag 
levels after LR. Intriguingly, vasopressin has been shown to stimulate vWF release and 
our study highlights that the clinical use of similar substances might be an attractive tool 
to promote liver regeneration. Indeed, this seems of specific interest as Fahrner et al. 
demonstrated that terlipressin (the long-acting analog of vasopressin) improved liver 
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regeneration in mice, potentially also by the increase of circulating vWF (15) and a 
clinical trial evaluating the relevance of this finding in humans is currently ongoing 
(ClinicalTrials.gov Identifier: NCT01921985). 
Of note, the measured amount of vWF-Ag highly significantly correlated with its activity 
assessed via vWF:RiCo. This specific test examines the capacity of vWF to bind to 
glycoprotein Ib, a central member of the vWF-receptor on the surface of platelets, and 
hence allows to quantify the function of vWF-Ag. Indeed, we observed an immediate 
increase of vWF:RiCo two hours after induction of liver regeneration and a subsequent 
increase up to POD1, parallel to vWF-Ag and a highly significant correlation of vWF-Ag 
and its function activity (vWF:RiCo). Interestingly, when normalizing vWF:RiCo to its 
absolute amount (vWF:RiCo/vWF-Ag) at the respective time points, we observed a 
mentionable trend towards decreased values in patients that ultimately developed LD. 
This finding is in line with previous reports on compensatory upregulation of vWF-Ag 
due to a functional loss in patients with diminished liver reserve(22) and further supports 
our proposed hypothesis on the disruption of vWF-dependent platelet accumulation 
within the regenerating liver in patients that will develop LD in the postoperative time 
course. Regarding the time course of normalized vWF-activity (vWF:RiCo/vWF-Ag), we 
found a significant increase during early liver regeneration, followed by a decrease on 
POD1, suggesting that a functional improvement of vWF-Ag takes place during this 
period of liver regeneration. Interestingly, this transient increase in vWF-activity per 
molecule supports the hypothesis that the increase in vWF-Ag in the liver vein two 
hours after ligation of the contralateral portal venous branch indeed arises from newly 
released compartments, as uncleaved high molecular weight vWF-Ag multimers are 
known to have a higher activity(23). Additionally, we did not observe any pre- or 
intraoperative changes or differences in ADAMTS13-activity, as the main cleavage 
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protease of vWF, between patients with and without LD, which suggests a minor role of 
ADAMTS13 during the early phase of liver regeneration. 
In the clinical routine, not only promotion of postoperative liver regeneration, but also 
preoperative risk stratification of patients undergoing LR to avoid postoperative 
morbidity and mortality represents an issue of critical relevance. While several invasive 
and non-invasive tests have been developed, only very few have found their way into 
routine clinical application. Major drawbacks of available predictors are availability, 
high costs and invasiveness(24). HVPG, the gold standard to evaluate portal hypertension, 
has been shown to be of value to predict postoperative clinical outcome in high-risk 
patients such as patients suffering from HCC(25-27). Despite several promising 
exploratory analyses, no non-invasive, easily assessable marker to predict postoperative 
outcome prior to LR has been identified so far. While the association of vWF-Ag levels 
and advanced liver disease, and portal hypertension has been established previously(8), 
its predictive impact in patients undergoing LR has not been evaluated in a large 
prospective clinical trial. Of note, vWF-Ag is easily assessable in patients’ blood and 
represents a low-cost routine blood parameter (about 6$/analysis) available in most 
clinical standard laboratories. Accordingly, our results show that preoperative vWF-Ag 
levels predict postoperative outcome in patients undergoing LR in a routine setting and 
are of major clinical relevance and applicability. Interestingly, we observed a close 
relation to markers of liver function and damage, and an association with preexisting 
liver cirrhosis. However, we were able to show an independency of vWF-Ag for the 
prediction of both LD and morbidity upon MVA. Importantly, the validation of our 
results in a multicenter international design, including several standard laboratories and 
clinical situations further demonstrates the clinical utility of this parameter and suggests 
that it may be applied in a clinical daily life setting. Using a vWF-Ag cut-off of 182% we 
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were able to define patients at risk of postoperative complications. Accordingly, vWF-Ag 
evaluation might help to tailor strategy and extent of surgical intervention to each 
individual patient and consider a less aggressive surgical approach or alternative 
treatment options. 
To our knowledge, this is the first report that provides evidence for the relevance of 
vWF during the process of human liver regeneration. We observed an immediate 
accumulation of platelets after induction of liver regeneration, which was associated 
with vWF-Ag levels. Importantly, we provided evidence that the immediate vWF burst 
after induction of liver regeneration has a direct effect on platelet accumulation and 
postoperative liver function recovery. Ultimately, we documented the predictive 
potential of vWF-Ag levels for clinical outcome after LR based on a large prospective 
clinical trial. Applying a cut-off at vWF-Ag≥182%, we were able to demonstrate that 
elevated preoperative vWF-Ag levels were vital to identify high-risk patients that 
suffered from an increased incidence of poor postoperative outcome. As vWF-Ag is a 
non-invasive, cost effective and easily assessable parameter, readily available in most 
routine laboratories, it represents an attractive clinical marker for distinguishing high 
and low risk patients prior to LR.  
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Figure Legends 
 
Fig.1 Perioperative vWF-Ag Time Course 
Von Willebrand Factor (vWF-Ag) was measured prior to surgery (PRE OP), on the first 
(POD1) and fifth (POD5) postoperative day. The perioperative time course of vWF-Ag 
(A) is illustrated and shown separately according to the extent of resection (B), liver 
dysfunction (LD) (C) and postoperative morbidity (D). ISGLS = international study 
group for liver surgery, *P<0.05, **P<0.005 
 
Fig.2 Dynamics of vWF-Ag and Platelets During Early Liver Regeneration 
Platelet (PLT) accumulation within the liver sinusoids was assessed prior to portal vein 
ligation and from the regenerating liver lobe at the end of liver surgery (A). Von 
Willebrand Factor (WF-Ag) and platelet count were assessed in the liver vein (LV) of the 
regenerating liver lobe and compared to preoperative levels (PRE OP) (B) VWF-Ag was 
compared between patients with and without liver dysfunction (LD) (C). Same was done 
for calculated fold increase of vWF-Ag (D). Incidence of LD is shown for patients with or 
without significant increase of vWF-Ag after induction of liver regeneration (E) and fold 
change of vWF-Ag was compared between patients that decreased in their platelet count 
and patients that did not show a reduction in platelets (F). *P<0.05, **P<0.005 
 
Fig.3 Functional Aspects of vWF-Ag In the Early Phase of Liver Regeneration 
Dynamics of ristocetin cofactor (vWF:RiCo) were assessed peri- and intraoperatively 
(A). Further, vWF:RiCo was compared between patients with and without liver 
dysfunction (LD) (A). We observed a strong correlation of von Willebrand Factor (vWF-
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Ag) and vWF:RiCo (B). VWF:RiCo to vWF-Ag was calculated is shown in the time course 
and was compared between patients with and without LD (C). Ultimately, also the 
activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif 
member 13 (ADAMTS13) was evaluated and perioperative dynamics are shown for all 
patients, and separately for patients with and without liver dysfunction (D). PRE OP = 
preoperative, LV = liver vein, POD = postoperative day, *P<0.05, **P<0.005 
 
Fig.4 VWF-Ag and Prediction of Postoperative Outcome: Exploration-Cohort 
A illustrates preoperative receiver operating characteristic (ROC)-curve analysis of von 
Willebrand Factor (vWF-Ag) to predict postoperative liver dysfunction (LD) and shows 
the incidence of postoperative LD and of postoperative morbidity according to the 
defined cut-off value for preoperative (182%) vWF-Ag. B illustrates postoperative ROC-
curve analysis of vWF-Ag to predict postoperative liver dysfunction (LD) and shows the 
incidence of postoperative LD and of postoperative morbidity according to the defined 
cut-off value for postoperative vWF-Ag (315%). C illustrates the validation of the 
predictive potential of the preoperative cut-off of 182% vWF-Ag in an independent 
validation cohort. AUC = area under the curve, ISGLS = international study group for 
liver surgery, *P<0.05, **P<0.005 
 
Fig.5 Preoperative vWF-Ag and Prediction of Poor Postoperative Performance, ICU-Stay 
and Hospitalization: Entire Cohort 
The incidence of postoperative liver dysfunction (LD) (A), postoperative morbidity (B), 
prolonged intensive care unit (ICU) (C) and hospital stay (D), and 90 days mortality (D), 
are shown according to the defined cut-off value for preoperative von Willebrand Factor 
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(vWF-Ag) (182%). ISGLS = international study group for liver surgery, POD = 
postoperative day,*P<0.05, **P<0.005 
 
Fig.6 Summary of Proposed Mechanism of Action of vWF during the Early Phase of Liver 
Regeneration.  
LR = liver regeneration, OP = operation, LD=liver dysfunction, PVP = portal venous 
pressure, PL = platelets, WB = Weibel-Palade bodies, vWF = von Willebrand Factor. 
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Table 1. Patient Demographics 
Parameter 
Collective(N=228) Exploration–Set(N=95) Validation–Set(N=133) 
N(%), median (range) N(%), median (range) N(%), median (range) 
Age (years) 61.4(22.0–89.0) 64.4(22.0–89.0) 60.4(24.0–84.0) 
Sex    
Male 150(65.8) 65(68.4) 85(63.9) 
Female 78(34.2) 30(31.6) 48(36.1) 
Neoplastic entity    
mCRC 101(44.3) 53(55.8) 48(36.1) 
HCC 52(22.8) 25(26.3) 27(20.3) 
CCC 44(19.3) 17(17.9) 27(20.3) 
non-neoplastic 10(4.4) 0(0.0) 10(7.5) 
others 21(9.2) 0(0.0) 21(15.8) 
Preoperative CTx    
yes 97(42.5) 54(56.8) 43(32.3) 
Hepatic resection    
major 125(54.8) 52(54.7) 73(54.9) 
minor 103(45.2) 43(45.3) 60(45.1) 
Postoperative LD    
yes 28(12.3) 13(13.7) 15(11.3) 
Morbidity    
yes 108(47.4) 50(52.6) 58(43.6) 
90 days mortality    
yes 9(3.9) 2(2.1) 7(5.3) 
Preoperative parameters 
vWF-Ag % 163(51-420) 160(51–420) 167(58–420) 
SB mg/dl 0.6(0.1–6.9) 0.6(0.2–6.6) 0.6(0.1–6.9) 
INR 1.1(0.0–2.2) 0.9(0.7–1.9) 1.1(0.0–2.2) 
ALP U/l  89.0(35.0–741.0) 87.5(43.0–423.0) 90.0(35.0–741.0) 
GGT U/l 62.5(8.0–2324.0) 62.0(11.0–710.0) 66.0(8.0–2324.0) 
AST U/l 30.0(14.0–1035.0) 31.0(17.0–208.0) 29.5(14.0–1035.0) 
ALT U/l 30(6–1122) 30(7–196) 30(6–1122) 
Albumin g/l 41.9(1.7–54.0) 41.9(30.2–49.6) 42.0(1.7–54.0) 
Platelets x10
3
/µl 223.5(66.0–582.0) 221.5(86.0–492.0) 225.5(66.0–582.0) 
MELD Score 7(6–15) 7(6–15) 7(6-12) 
ICU–days 1(0–39) 1(0–25) 1(0–39) 
ALT=alanine aminotransferase, ALP=alkaline phosphatase, AST=aspartate aminotransferase, CCC=cholangiocellular carcinoma, 
CTx=chemotherapy, GGT=gamma-glutamyl-transferase, HCC=hepatocellular carcinoma, INR=internationalized normalized ratio, LD=liver 
dysfunction, mCRC=metastatic colorectal cancer, MELD=model of end-stage liver disease, SB=serum bilirubin. 
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Table 2. Predictors of Postoperative Liver Dysfunction and Morbidity 
 univariate logistic regression multivariable logistic regression 
 
LD OR 95 % CI P-value OR 95 % CI P-value 
vWF-Ag % 1.007 1.002-1.012 0.004 1.009 1.003-1.014 0.003 
Gender 1.112 0.478-2.589 0.81    
Age 1.283 0.408-4.027 0.67    
Neoplastic entity  .     
mCRC 0.299 0.116-0.768 0.01    
HCC 2.981 1.307-6.802 0.009    
CCC 1.811 0.739-4.436 0.19    
benign n.a. n.a. n.a.    
Others 0.774 0.170-3.528 0.74    
Preoperative CTx 0.255 0.093-0.698 0.008 0.244 0.080-0.740 0.01 
Extend resection 8.333 2.438-28.488 0.001 10.177 2.747-37.703 0.001 
Preoperative paramters        
SB mg/dl 0.999 0.589-1.696 0.10    
INR 8.531 1.464-49.712 0.02 8.156 1.056-62.996 0.04 
ALP U/l 1.003 1.000-1.007 0.02    
GGT U/l 1.001 1.000-1.002 0.06    
AST U/l 1.000 0.995-1.005 0.95    
ALT U/l 1.000 0.995-1.004 0.92    
Albumin g/l 0.928 0.879-0.980 0.007    
Platelets (x103/µl) 0.997 0.991-1.002 0.24    
MELD Score 1.315 1.059-1.634 0.013    
Liver pathoistology       
SOS 0.508 0.059-4.350 0.537    
Steatohepatitis 1.071 0.285-4.029 0.919    
Steatosis 2.129 0.600-7.550 0.242    
Degree of 
Fibrosis 3.160 0.993-10.057 0.051    
RBC transfusion 1.109 0.356-3.453 0.858    
Anti-platelet drugs 1.311 0.246-6.981 0.751    
       
Morbidity 
vWF-Ag % 1.006 1.002-1.010 0.003 1.007 1.003-1.011 0.001 
Gender 1.260 0.727-2.184 0.41    
Age 1.452 0.647-3.257 0.37    
Neoplastic entity       
mCRC 0.577 0.340-0.982 0.04    
HCC 1.282 0.690-2.384 0.43    
CCC 5.995 2.720-13.214 <0.001 5.958 2.565-13.837 <0.001 
benign 0.116 0.014-0.934 0.04    
Others 0.252 0.082-0.781 0.02    
Preoperative CTx 0.521 0.305-0.890 0.02    
Extend resection 3.441 1.984-5.968 <0.001 3.359 1.848-6.104 <0.001 
Preoperative paramters        
SB mg/dl 1.470 0.954-2.266 0.08    
INR 2.418 0.630-9.278 0.20    
ALP U/l 1.004 1.001-1.007 0.01    
GGT U/l 1.001 1.000-1.002 0.09    
AST U/l 1.001 0.998-1.004 0.45    
ALT U/l 1.001 0.998-1.005 0.44    
Albumin g/l 0.935 0.876-0.997 0.04    
Platelets (x103/µl) 0.999 0.995-1.002 0.55    
MELD Score 1.278 1.060-1.541 0.01    
Liver pathohistology       
SOS 0.292 0.074-1.150 0.078    
Steatohepatitis 0.810 0.321-2.043 0.655    
Steatosis 1.083 0.477-2.459 0.849    
Degree of 
Fibrosis 1.638 0739-3.631 0.224    
RBC transfusion 0.978 0.453-2.113 0.956    
Anti-platelet drugs 1.801 0.483-6.717 0.381    
ALT=alanine aminotransferase, ALP=alkaline phosphatase, AST=aspartate aminotransferase, CCC=cholangiocellular 
carcinoma, CTx=chemotherapy, GGT=gamma-glutamyltransferase, HCC=hepatocellular carcinoma, INR=international 
normalized ratio, mCRC=metastatic colorectal cancer, n.a.=not assessable, SB=serum bilirubin, SOS=sinusoidal obstruction 
syndrome, RBC=red blood cells. 
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Fig.1 Perioperative vWF-Ag Time Course  
Von Willebrand Factor (vWF-Ag) was measured prior to surgery (PRE OP), on the first (POD1) and fifth 
(POD5) postoperative day. The perioperative time course of vWF-Ag (A) is illustrated and shown separately 
according to the extent of resection (B), liver dysfunction (LD) (C) and postoperative morbidity (D). ISGLS = 
international study group for liver surgery, *P<0.05, **P<0.005  
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Fig.2 Dynamics of vWF-Ag and Platelets During Early Liver Regeneration  
Platelet (PLT) accumulation within the liver sinusoids was assessed prior to portal vein ligation and from the 
regenerating liver lobe at the end of liver surgery (A). Von Willebrand Factor (WF-Ag) and platelet count 
were assessed in the liver vein (LV) of the regenerating liver lobe and compared to preoperative levels (PRE 
OP) (B) VWF-Ag was compared between patients with and without liver dysfunction (LD) (C). Same was 
done for calculated fold increase of vWF-Ag (D). Incidence of LD is shown for patients with or without 
significant increase of vWF-Ag after induction of liver regeneration (E) and fold change of vWF-Ag was 
compared between patients that decreased in their platelet count and patients that did not show a reduction 
in platelets (F). *P<0.05, **P<0.005  
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Fig.3 Functional Aspects of vWF-Ag In the Early Phase of Liver Regeneration  
Dynamics of ristocetin cofactor (vWF:RiCo) were assessed peri- and intraoperatively (A). Further, vWF:RiCo 
was compared between patients with and without liver dysfunction (LD) (A). We observed a strong 
correlation of von Willebrand Factor (vWF-Ag) and vWF:RiCo (B). VWF:RiCo to vWF-Ag was calculated is 
shown in the time course and was compared between patients with and without LD (C). Ultimately, also the 
activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13) 
was evaluated and perioperative dynamics are shown for all patients, and separately for patients with and 
without liver dysfunction (D). PRE OP = preoperative, LV = liver vein, POD = postoperative day, *P<0.05, 
**P<0.005  
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Fig.4 VWF-Ag and Prediction of Postoperative Outcome: Exploration-Cohort  
A illustrates preoperative receiver operating characteristic (ROC)-curve analysis of von Willebrand Factor 
(vWF-Ag) to predict postoperative liver dysfunction (LD) and shows the incidence of postoperative LD and of 
postoperative morbidity according to the defined cut-off value for preoperative (182%) vWF-Ag. B illustrates 
postoperative ROC-curve analysis of vWF-Ag to predict postoperative liver dysfunction (LD) and shows the 
incidence of postoperative LD and of postoperative morbidity according to the defined cut-off value for 
postoperative vWF-Ag (315%). C illustrates the validation of the predictive potential of the preoperative cut-
off of 182% vWF-Ag in an independent validation cohort. AUC = area under the curve, ISGLS = international 
study group for liver surgery, *P<0.05, **P<0.005  
 
254x190mm (300 x 300 DPI)  
 
 
Page 35 of 44
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
Fig.5 Preoperative vWF-Ag and Prediction of Poor Postoperative Performance, ICU-Stay and Hospitalization: 
Entire Cohort  
The incidence of postoperative liver dysfunction (LD) (A), postoperative morbidity (B), prolonged intensive 
care unit (ICU) (C) and hospital stay (D), and 90 days mortality (D), are shown according to the defined 
cut-off value for preoperative von Willebrand Factor (vWF-Ag) (182%). ISGLS = international study group 
for liver surgery, POD = postoperative day,*P<0.05, **P<0.005  
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Fig.6 Summary of Proposed Mechanism of Action of vWF during the Early Phase of Liver Regeneration.  
LR = liver regeneration, OP = operation, LD=liver dysfunction, PVP = portal venous pressure, PL = platelets, 
WB = Weibel-Palade bodies, vWF = von Willebrand Factor.  
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